Clinical Trial Update: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% [Phase 2]

View source ↗

Summary

Phase 2 preoperative window study compares giredestrant with tamoxifen in premenopausal ER+/HER2− breast cancer with Ki67 ≥10%. The study has completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Early-onset Breast Cancer

Drugs mentioned

• Giredestrant (giredestrant)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer, Breast Cancer, Early-Onset | Phase 2 | Status: COMPLETED | Results posted: 2026-03-19